OncoSec Medical Inc. To Evaluate Increased Dose Frequency Of ImmunoPulse In Ongoing Phase II Melanoma Trial
3/12/2014 8:39:59 AM
SAN DIEGO--(BUSINESS WIRE)--OncoSec Medical Inc. (OTCQB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy to treat solid tumors, announced today that the company has submitted a protocol addendum to the FDA and institutional IRBs to evaluate an increased dose frequency for ImmunoPulse in an expansion of its ongoing Phase II melanoma trial. The Company expects to enroll up to 21 patients in this expansion, and expects two additional key cancer centers as sites participating in this study.
Help employers find you! Check out all the jobs and post your resume.
comments powered by